Mankind Pharma

2,333.40
+29.90
(1.30%)
ann
There are new updates from the company1 day ago
Viewcross
right
Market Cap
95,037.50 Cr
EPS
47.75
PE Ratio
47.84
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
3,054.80
52 Week Low
1,901.05
PB Ratio
6.63
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+68.75 %
+68.75 %
Hold
Hold+18.75 %
+18.75 %
Sell
Sell+12.50 %
+12.50 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,687.60
#1 4,00,641.00
34.92
#1 49,887.20
12.06
#1 9,648
-18.99
51.79
6,658.00
1,75,634.00
80.14
8,184.00
0.89
1,600
23.05
57.57
1,502.40
1,22,256.70
23.74
28,409.50
7.12
5,291
30.28
51.21
1,301.00
1,10,273.30
19.50
28,905.40
12.36
5,578
21.14
51.26
3,341.40
1,09,064.00
56.62
10,785.70
11.59
1,656
10.91
65.60
981.80
98,807.10
21.16
19,831.50
13.82
3,831
-0.19
66.87
2,333.40
#7 95,037.50
#7 47.84
#8 10,615.60
#2 19.57
#6 1,942
#9 -10.91
42.68
1,935.20
88,053.10
26.80
20,141.50
#1 19.94
1,936
#1 112.49
42.45
34,940.00
70,239.60
49.80
6,097.20
10.80
1,201
27.83
77.32
1,121.00
65,235.60
#1 18.88
29,559.20
17.55
3,169
-0.50
44.15
Forecast
Actual
Growth Rate
Revenue Growth
19.57 %
Net Income Growth
48.26 %
Cash Flow Change
18.70 %
ROE
18.04 %
ROCE
13.14 %
EBITDA Margin (Avg.)
16.05 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,517
2,998
3,189
3,286
3,333
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,836
2,212
2,227
2,383
2,401
EBITDA
323
476
622
477
467
718
746
681
681
786
962
903
933
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
24 %
28 %
26 %
22 %
Depreciation
47
78
79
85
85
87
97
110
100
108
106
187
231
Interest
13
16
10
13
5
6
9
9
9
11
7
221
191
Profit Before Tax
263
382
533
379
377
625
641
562
572
668
849
495
511
Tax
70
84
110
83
84
130
130
103
95
125
190
111
86
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
425
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.46
10.19

Balance Sheet

Balance Sheet
2022
2023
2024
Total Assets
9,148
9,715
11,963
Fixed Assets
3,588
4,251
4,545
Current Assets
4,407
4,328
6,568
Capital Work in Progress
702
550
282
Investments
1,110
1,346
2,568
Other Assets
3,749
3,568
4,568
Total Liabilities
9,148
9,715
11,963
Current Liabilities
2,624
1,863
2,120
Non Current Liabilities
208
229
268
Total Equity
6,316
7,623
9,576
Reserve & Surplus
6,115
7,395
9,323
Share Capital
40
40
40

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
Net Cash Flow
103
-92
156
22
77
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
Operating Activities
1,070
1,137
920
1,813
2,152
Financing Activities
-531
-8
605
-740
5

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
72.70 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
12.92 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
11.48 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
1.64 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
1.26 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431
1,80,597

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 May 2025 2,430.05 2,550.70
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 2,738.25 2,515.05
05 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2024 2,506.95 2,734.95
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 2,114.50 2,068.60

Announcements

Closure of Trading Window1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 10, 2025
Intimation Under Regulations 30 & 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Environmental Social And Governance (ESG) RatingJun 04, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 21, 2025
Appointment Of Cost Auditor And Secretarial AuditorMay 21, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 21, 2025
Outcome Of Board MeetingMay 21, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 21, 2025
Outcome Of Board MeetingMay 21, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 15, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 14, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 11, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 09, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 50 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 08, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 06, 2025
Release Of Pledge On The Shares Of Bharat Serums And Vaccines Limited A Wholly Owned Subsidiary Of The CompanyMay 02, 2025
Announcement under Regulation 30 (LODR)-AcquisitionApr 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On April 14 2025Apr 14, 2025
Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017) Apr 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationMar 29, 2025
Effective Date Of The Scheme Of Arrangement For Amalgamation Amongst Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedMar 29, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementMar 28, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 25, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 01, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Update On Scheme Of Arrangement For Amalgamation Of Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedFeb 27, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 18, 2025
Final Update On Stake Sale Of Mahananda Spa And Resorts Private LimitedFeb 11, 2025
Announcement under Regulation 30 (LODR)-Diversification / DisinvestmentFeb 10, 2025
Board Meeting Outcome for Mankind Pharma Limited Has Informed The Exchange Regarding Sale Of Entire Stake In Mahananda Spa And Resorts Private LimitedFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 04, 2025

Technical Indicators

RSI(14)
Neutral
35.37
ATR(14)
Volatile
50.59
STOCH(9,6)
Oversold
18.30
STOCH RSI(14)
Neutral
32.02
MACD(12,26)
Bearish
-2.72
ADX(14)
Weak Trend
12.44
UO(9)
Bearish
32.92
ROC(12)
Downtrend And Accelerating
-3.17
WillR(14)
Oversold
-84.99

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Invesco India Large & Mid Cap Fund Direct-Growth
0.00%
-399741
-1.46%
-1.51%
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
0.13%
-162845
-0.28%
-0.28%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.00%
-158550
-0.28%
-0.40%
Mirae Asset Aggressive Hybrid Fund Direct-Growth
0.00%
-126288
-0.35%
-0.47%
Axis Large Cap Fund Direct-Growth
0.32%
-122870
-0.09%
-0.20%
Nippon India Pharma Fund Direct-Growth
2.24%
108460
0.30%
0.29%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.00%
-107849
-0.06%
-0.08%
Sundaram Multi Asset Allocation Fund Direct - Growth
0.56%
60000
0.56%
0.56%
Axis India Manufacturing Fund Direct-Growth
0.43%
-59248
-0.29%
-0.47%
Bandhan Flexi Cap Fund Direct-Growth
1.17%
50000
0.14%
-0.21%
Canara Robeco Focused Fund Direct - Growth
2.19%
-49511
-0.58%
-0.59%
Mirae Asset Healthcare Fund Direct - Growth
2.49%
-47529
-0.44%
-0.61%
Sundaram Large and Mid Cap Fund Direct-Growth
1.33%
43712
0.14%
0.57%
Kotak Equity Arbitrage Fund Direct-Growth
0.01%
35325
0.01%
0.01%
Mirae Asset Balanced Advantage Fund Direct - Growth
0.00%
-27182
-0.37%
-0.50%
Mirae Asset Multi Asset Allocation Fund Direct - Growth
0.00%
-23002
-0.30%
-0.42%
Union Multi Asset Allocation Fund Direct-Growth
0.00%
-22500
-0.69%
-0.69%
Axis ESG Integration Strategy Fund Direct-Growth
0.00%
-20954
-0.42%
-0.42%
Sundaram Mid Cap Fund Direct-Growth
0.93%
19105
-0.01%
0.03%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
-18570
-1.43%
-1.12%
Union Aggressive Hybrid Fund Direct - Growth
0.00%
-18000
-0.70%
-0.71%
Aditya Birla Sun Life India GenNext Direct Fund-Growth
0.28%
15000
0.06%
0.05%
Aditya Birla Sun Life ESG Integration Strategy Fund Direct-Growth
1.16%
15000
0.57%
0.56%
Nippon India Arbitrage Fund Direct-Growth
0.02%
13275
0.02%
0.02%
Mirae Asset Equity Savings Fund Direct - Growth
0.00%
-12027
-0.21%
-0.36%

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years, 18 days)
Chairperson NameRAMESH CHAND JUNEJA
OSZAR »